AU2016259054B2 - Solid forms - Google Patents
Solid forms Download PDFInfo
- Publication number
- AU2016259054B2 AU2016259054B2 AU2016259054A AU2016259054A AU2016259054B2 AU 2016259054 B2 AU2016259054 B2 AU 2016259054B2 AU 2016259054 A AU2016259054 A AU 2016259054A AU 2016259054 A AU2016259054 A AU 2016259054A AU 2016259054 B2 AU2016259054 B2 AU 2016259054B2
- Authority
- AU
- Australia
- Prior art keywords
- xrpd
- solid form
- 2theta
- form according
- particular embodiment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/40—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
- C07C209/78—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton from carbonyl compounds, e.g. from formaldehyde, and amines having amino groups bound to carbon atoms of six-membered aromatic rings, with formation of methylene-diarylamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/82—Purification; Separation; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/82—Purification; Separation; Stabilisation; Use of additives
- C07C209/84—Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166641.9 | 2015-05-06 | ||
| EP15166641.9A EP3090998A1 (en) | 2015-05-06 | 2015-05-06 | Solid forms |
| PCT/EP2016/059726 WO2016177656A1 (en) | 2015-05-06 | 2016-05-02 | Solid forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016259054A1 AU2016259054A1 (en) | 2017-11-16 |
| AU2016259054B2 true AU2016259054B2 (en) | 2020-08-13 |
Family
ID=53039825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016259054A Active AU2016259054B2 (en) | 2015-05-06 | 2016-05-02 | Solid forms |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10221125B2 (https=) |
| EP (2) | EP3090998A1 (https=) |
| JP (2) | JP7005007B2 (https=) |
| KR (1) | KR102666390B1 (https=) |
| CN (1) | CN107735394B (https=) |
| AR (1) | AR104505A1 (https=) |
| AU (1) | AU2016259054B2 (https=) |
| BR (1) | BR112017023740B1 (https=) |
| CA (1) | CA2984203C (https=) |
| ES (1) | ES2969970T3 (https=) |
| HU (1) | HUE065558T2 (https=) |
| IL (1) | IL255194B (https=) |
| MX (1) | MX378732B (https=) |
| PL (1) | PL3292100T3 (https=) |
| WO (1) | WO2016177656A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX356344B (es) | 2011-10-20 | 2018-05-23 | Oryzon Genomics Sa | Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1. |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| ES3057783T3 (en) | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| CN109462980B (zh) | 2016-03-15 | 2022-02-08 | 奥莱松基因组股份有限公司 | 用于治疗血液恶性肿瘤的lsd1抑制剂的组合 |
| WO2017158136A1 (en) | 2016-03-16 | 2017-09-21 | Oryzon Genomics, S.A. | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| RS58951B1 (sr) | 2016-06-10 | 2019-08-30 | Oryzon Genomics Sa | Lečenje multiple skleroze |
| MX2020001323A (es) | 2017-08-03 | 2020-03-20 | Oryzon Genomics Sa | Metodos para tratar alteraciones del comportamiento. |
| SG11202010124SA (en) * | 2018-05-04 | 2020-11-27 | Oryzon Genomics Sa | Stable pharmaceutical formulation |
| SG11202109159VA (en) | 2019-03-20 | 2021-10-28 | Oryzon Genomics Sa | Methods of treating borderline personality disorder |
| ES3053813T3 (en) | 2019-03-20 | 2026-01-26 | Oryzon Genomics Sa | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
| CA3132473A1 (en) * | 2019-03-25 | 2020-10-01 | Oryzon Genomics, S.A. | Combinations of iadademstat for cancer therapy |
| CN114341366A (zh) | 2019-07-05 | 2022-04-12 | 奥莱松基因组股份有限公司 | 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法 |
| JP2024513260A (ja) | 2021-04-08 | 2024-03-22 | オリゾン ジェノミックス ソシエダッド アノニマ | 骨髄癌処置のためのｌｓｄ１阻害剤の組み合わせ |
| JP2025516648A (ja) | 2022-05-09 | 2025-05-30 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法 |
| CN119546292A (zh) | 2022-05-09 | 2025-02-28 | 奥莱松基因组股份有限公司 | 使用lsd1抑制剂治疗恶性周围神经鞘瘤(mpnst)的方法 |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013057322A1 (en) * | 2011-10-20 | 2013-04-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE554184T1 (de) | 2004-12-16 | 2012-05-15 | Harvard College | Durch das nukleäre aminoxidase-homolog lsd1 vermittelte histondemethylierung |
| DE602005022826D1 (de) | 2005-02-18 | 2010-09-23 | Universitaetsklinikum Freiburg | Kontrolle der Androgen Rezeptor-abhängigen Gen Expression durch Hemmung der Aminoxidase Aktivität der Lysin spezifischen Demethylase (LSD1) |
| CA2619005A1 (en) | 2005-08-10 | 2007-02-22 | Johns Hopkins University | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors |
| WO2008127734A2 (en) | 2007-04-13 | 2008-10-23 | The Johns Hopkins University | Lysine-specific demethylase inhibitors |
| WO2010011845A2 (en) | 2008-07-24 | 2010-01-28 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods of preventing or treating viral infection or reactivation after latency in a host using inhibitors of the lsd1 protein |
| EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| EP2258865A1 (en) | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer |
| JPWO2010143582A1 (ja) | 2009-06-11 | 2012-11-22 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤 |
| EP2467359A4 (en) | 2009-08-18 | 2013-01-09 | Univ Johns Hopkins | (BIS-) UREA- AND (BIS-) THIOMINE COMPOUNDS AS EPIGENE MODULATORS OF THE LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF DISEASE TREATMENT THEREWITH |
| RU2602814C2 (ru) | 2009-09-25 | 2016-11-20 | Оризон Дженомикс С.А. | Лизинспецифические ингибиторы деметилазы-1 и их применение |
| US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
| WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| WO2011106573A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| WO2011113005A2 (en) | 2010-03-12 | 2011-09-15 | The Johns Hopkins University | Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (dfmo) |
| RS55348B1 (sr) | 2010-04-19 | 2017-03-31 | Oryzon Gnomics S A | Inhibitori lizin specifične demetilaze-1 i njihova upotreba |
| CN102985402B (zh) | 2010-04-20 | 2015-04-29 | 罗马大学 | 反苯环丙胺衍生物作为组蛋白去甲基酶lsd1和/或lsd2的抑制剂 |
| EP2598480B1 (en) | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| WO2012013728A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
| US9527805B2 (en) | 2010-09-10 | 2016-12-27 | Robert A. Casero | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| WO2012107498A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| US20140163041A1 (en) | 2011-02-08 | 2014-06-12 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
| EA023143B1 (ru) | 2011-03-25 | 2016-04-29 | Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед | Замещенный циклопропиламин в качестве ингибитора lsd1 |
| EP2741741A2 (en) | 2011-05-19 | 2014-06-18 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
| US20140296255A1 (en) | 2011-05-19 | 2014-10-02 | Oryzong Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
| MX356344B (es) | 2011-10-20 | 2018-05-23 | Oryzon Genomics Sa | Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1. |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| CA2987876A1 (en) | 2015-06-12 | 2016-12-15 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| WO2017060319A1 (en) | 2015-10-09 | 2017-04-13 | F. Hoffmann-La Roche Ag | Gene expression biomarkers for personalized cancer care to epigenetic modifying agents |
| CN109462980B (zh) | 2016-03-15 | 2022-02-08 | 奥莱松基因组股份有限公司 | 用于治疗血液恶性肿瘤的lsd1抑制剂的组合 |
| ES3057783T3 (en) | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| WO2017158136A1 (en) | 2016-03-16 | 2017-09-21 | Oryzon Genomics, S.A. | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| WO2018083138A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
-
2015
- 2015-05-06 EP EP15166641.9A patent/EP3090998A1/en not_active Ceased
-
2016
- 2016-05-02 PL PL16719864.7T patent/PL3292100T3/pl unknown
- 2016-05-02 CA CA2984203A patent/CA2984203C/en active Active
- 2016-05-02 WO PCT/EP2016/059726 patent/WO2016177656A1/en not_active Ceased
- 2016-05-02 MX MX2017014035A patent/MX378732B/es unknown
- 2016-05-02 CN CN201680025229.8A patent/CN107735394B/zh active Active
- 2016-05-02 JP JP2017557899A patent/JP7005007B2/ja active Active
- 2016-05-02 KR KR1020177035160A patent/KR102666390B1/ko active Active
- 2016-05-02 EP EP16719864.7A patent/EP3292100B1/en active Active
- 2016-05-02 ES ES16719864T patent/ES2969970T3/es active Active
- 2016-05-02 BR BR112017023740-7A patent/BR112017023740B1/pt active IP Right Grant
- 2016-05-02 US US15/571,945 patent/US10221125B2/en active Active
- 2016-05-02 AU AU2016259054A patent/AU2016259054B2/en active Active
- 2016-05-02 HU HUE16719864A patent/HUE065558T2/hu unknown
- 2016-05-03 AR ARP160101249A patent/AR104505A1/es unknown
-
2017
- 2017-10-22 IL IL255194A patent/IL255194B/en active IP Right Grant
-
2021
- 2021-03-31 JP JP2021060013A patent/JP2021119136A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013057322A1 (en) * | 2011-10-20 | 2013-04-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| CAIRA, "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, (1998-01), vol. 198, ISSN 0340-1022, pages 163 - 208 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2984203C (en) | 2024-07-02 |
| JP7005007B2 (ja) | 2022-02-04 |
| EP3090998A1 (en) | 2016-11-09 |
| EP3292100C0 (en) | 2023-11-15 |
| ES2969970T3 (es) | 2024-05-23 |
| US20180086692A1 (en) | 2018-03-29 |
| KR102666390B1 (ko) | 2024-05-21 |
| EP3292100A1 (en) | 2018-03-14 |
| HUE065558T2 (hu) | 2024-06-28 |
| JP2018516883A (ja) | 2018-06-28 |
| JP2021119136A (ja) | 2021-08-12 |
| HK1245235A1 (zh) | 2018-08-24 |
| CA2984203A1 (en) | 2016-11-10 |
| MX378732B (es) | 2025-03-11 |
| BR112017023740A2 (pt) | 2018-07-17 |
| PL3292100T3 (pl) | 2024-04-22 |
| CN107735394A (zh) | 2018-02-23 |
| CN107735394B (zh) | 2021-11-02 |
| EP3292100B1 (en) | 2023-11-15 |
| IL255194B (en) | 2021-03-25 |
| BR112017023740B1 (pt) | 2023-11-07 |
| MX2017014035A (es) | 2018-03-01 |
| AR104505A1 (es) | 2017-07-26 |
| AU2016259054A1 (en) | 2017-11-16 |
| HK1252089A1 (en) | 2019-05-17 |
| WO2016177656A1 (en) | 2016-11-10 |
| KR20180022660A (ko) | 2018-03-06 |
| IL255194A0 (en) | 2017-12-31 |
| US10221125B2 (en) | 2019-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016259054B2 (en) | Solid forms | |
| JP7379680B2 (ja) | テルフェニル化合物の新規な塩 | |
| AU2020276695A1 (en) | New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer | |
| ES2922158T3 (es) | Compuestos cristalinos | |
| CN1714098A (zh) | β－L－2'－脱氧胸苷的结晶形及非晶形 | |
| CN112020506A (zh) | 新生霉素类似物与脯氨酸的共晶体形式 | |
| US12384784B2 (en) | Polymorphs of Acalabrutinib, a Bruton's tyrosine kinase inhibitor | |
| HK1252089B (en) | Solid forms | |
| US7824710B2 (en) | Crystalline and stable form of andolast | |
| HK1245235B (zh) | 固体形式 | |
| CN108137626B (zh) | Fosnetupitant的晶型 | |
| WO2013082302A1 (en) | Agomelatine-urea complex and crystalline forms thereof | |
| WO2012003413A1 (en) | Novel solid forms of tacedinaline | |
| US20110313044A1 (en) | Polymorphs of Suberoylanilide Hydroxamic Acid | |
| WO2026046981A1 (en) | Solid forms of 5-[3-[[(3r)-1-ethyl-3-piperidyl]amino]-5-methyl-1,2,4-triazin-6-yl]-2,3- dihydrobenzofuran-4-ol | |
| US20220298158A1 (en) | Polymorph of venetoclax and method for preparing the polymorph | |
| HK40108981A (zh) | 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式 | |
| CA3170562A1 (en) | Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine | |
| JP2007302560A (ja) | 医薬化合物 | |
| JP2007302559A (ja) | 医薬化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |